Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
US6613519B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 23, 2001 |
| Grant date | Sep 2, 2003 |
| Priority date | — |
| Expiry date | Apr 3, 2021 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/32
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method and kit of evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD) is disclosed. The method comprises determining a haptoglobin phenotype of the diabetic patient and thereby evaluating the risk of the diabetic patient to develop the cardiovascular disease (CVD), wherein the risk is decreased in diabetic patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes. The risk is also decreased in diabetic patients with haptoglobin 1-2 phenotype as compared to patients with haptoglobin 2-2 phenotype. The kit comprises packaged reagents for determining a haptoglobin phenotype of the diabetic patient and the kit is identified for use in evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.